We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Preparation and characterization of a polyclonal antibody against PTEN‐Long.
- Authors
Yi, Xianyanling; Wang, Zhihong; Xiong, Xingyu; Zheng, Xiaonan; Peng, Ge; Xu, Hang; Wei, Qiang; Li, Hong; Zhu, Ye; Ai, Jianzhong
- Abstract
Phosphatase and tensin homolog‐long (PTEN‐L) is a translational isoform of PTEN, which exists in both intracellular and extracellular locations. Previous studies demonstrated that PTEN‐L could inhibit oncogenesis due to its lipid phosphatase activity. However, recent studies found that PTEN‐L could promote the proliferation of some types of cancer cells. Moreover, as a protein phosphatase, PTEN‐L can suppress mitophagy by counteracting PTEN‐induced putative kinase protein 1 (PINK1)‐Parkin‐mediated ubiquitin phosphorylation, namely, PTEN‐L is critical for exploring the mitophagy progression and the treatment of mitochondrial diseases. Accounting for the critical functions of PTEN‐L, its antibody can be used for the treatment or prognosis of tumors and mitochondrial diseases. Currently, the commercial antibody of PTEN‐L is not available. In our study, the recombinant PTEN‐L protein was expressed in Escherichia coli BL21 and used as an antigen to immunize Japan's big‐eared white rabbit for the preparation of polyclonal antibody. The PTEN‐L protein can be captured by PTEN‐L antibody specifically and effectively. Taken together, a PTEN_L antibody is a valuable tool for further exploring the function of PTEN‐L in oncogenesis and mitochondrial diseases, and it would be a new choice for the prognosis or treatment of cancer and mitochondrial diseases.
- Subjects
RECOMBINANT proteins; PHOSPHOPROTEIN phosphatases; CANCER cells; UBIQUITIN; PROTEIN kinases; IMMUNOGLOBULINS
- Publication
Biotechnology & Applied Biochemistry, 2022, Vol 69, Issue 4, p1622
- ISSN
0885-4513
- Publication type
Article
- DOI
10.1002/bab.2232